Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Search content at Johns Hopkins University
Home
Profiles
Research units
Research output
Esthesioneuroblastoma
Barbara A. Murphy
, Joseph M. Aulino
, Christine H. Chung
, Kim Ely
, Robert Sinard
, Anthony Cmelak
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Esthesioneuroblastoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Esthesioneuroblastoma
100%
Paranasal Sinuses
75%
Tumor
50%
Radiation Therapy
50%
Stage at Diagnosis
50%
Nasal Cavity
50%
Poorly Differentiated Tumors
50%
Cavernous Sinus
25%
Pathologic
25%
Resection
25%
5-year Survival
25%
Local Recurrence
25%
Locoregional Recurrence
25%
Distant Metastasis
25%
Recurrence Site
25%
TNM Staging
25%
Well-differentiated
25%
Locally Advanced Disease
25%
Multimodality
25%
Combination Chemotherapy
25%
Locally Advanced
25%
Histological Grade
25%
Progressive Course
25%
Staging System
25%
Disseminated Infection
25%
Popular
25%
Frontal Lobe
25%
Presentation Time
25%
Rare Tumors
25%
Sinonasal Squamous Cell Carcinoma (SNSCC)
25%
Nasal
25%
Rapidly Progressive
25%
Anosmia
25%
Local Structure
25%
Nodal Metastasis
25%
Epistaxis
25%
Dura
25%
Regional Metastasis
25%
Slow-growing Tumor
25%
Anterior Cranial Fossa
25%
Late Recurrence
25%
Nasal Congestion
25%
Vault
25%
Resectable Tumors
25%
Nasal Pain
25%
Kadish Stage
25%
Nodal Disease
25%
Unresectable Disease
25%
Early-stage Tumor
25%
First 2 Years
25%
Medicine and Dentistry
Recurrent Disease
100%
Nasal Glioma
100%
Tumor
100%
Paranasal Sinus
60%
Diseases
60%
Neoplasm
40%
Nasal Cavity
40%
Radiation Therapy
40%
Cavernous Sinus
20%
Distant Metastasis
20%
Cancer Staging
20%
Overall Survival
20%
Frontal Lobe
20%
Sinonasal Undifferentiated Carcinoma
20%
Rare Tumor
20%
Nodal Metastasis
20%
Epistaxis
20%
Dura Mater
20%
Disseminated Disease
20%
Regional Metastasis
20%
Nasal Congestion
20%
Anterior Cranial Fossa
20%
Anosmia
20%
Chemotherapy
20%